← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Creative Bio-Peptides, Inc.
Potomac, MD
$9,544,819
Total funding
7
Grants
Funding over time
peak $4.7M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,544,819 · 7
By mechanism
R44$7,774,023 · 3
R43$1,770,796 · 4
Investigators at Creative Bio-Peptides, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a Novel Chemokine Receptor Antagonist Peptide as a Non-Opioid Treatment for Relief of Chronic Pain$2,999,505
R44 · FY2021 · NS
A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)$1,381,306
R44 · FY2024 · AG
Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder$1,151,331
R44 · FY2021 · DA
Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder$1,123,774
R44 · FY2022 · DA
A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)$1,118,107
R44 · FY2025 · AG
Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease$499,860
R43 · FY2021 · AG
Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease$449,230
R43 · FY2020 · AG
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD$324,790
R43 · FY2023 · AG
A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence$321,800
R43 · FY2019 · DA
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD$175,116
R43 · FY2024 · AG